Everyone expressing an interest in taking part in the large phase 3 ASPro-PD ambroxol trial will be genetically screened, via PD Frontline, as part of the trial selection criteria. PD Frontline are currently prioritising people under the age of 75 who have been diagnosed with Parkinson’s.

Ambroxol and Parkinson’s – find out more here

Registration of interest form:

We also ask you to complete the form below to register your interest with us. This will help you stay up-to-date with Cure Parkinson’s research and fundraising news and direct you on to PD Frontline.

The start of the ASPro-PD study has experienced a delay due to work that was needed to reformulate the drug. In the Phase 2 study, the participants were required to take 21 pills of ambroxol per day (in addition to their Parkinson’s medication) to achieve the required dose. This was an heroic effort by the participants in the six-month study, but we knew that there would be a need to reformulate the drug for this larger and longer study to prevent people from pulling out of the study due to medication burden. At this time, we are unable to provide a set timeline for when recruitment will begin, but rest assured that we at Cure Parkinson’s are doing everything to help expedite the process, and we still remain committed to seeing ambroxol tested further in Parkinson’s. We know this news will be frustrating and disappointing for those of you who have put yourselves forward to participate in this ground-breaking trial, and we thank you for your continued patience.

We plan to begin releasing quarterly updates on the project for those who have registered their interest with us. If you have not already done so, you can register yourself for this using the form below. If you have any specific questions or concerns regarding this news, please contact our Recruitment and Retention Officer, Anaya.

Email Anaya